Predictive Oncology Inc. (POAI) Financial Statements
Industry: Finance Services
In fiscal 2025, Predictive Oncology reported revenue of $125,284, down 92.3% from $1.6M the year before. Net income was -$233.1M (a -186053.4% net margin), or -$13.37 per diluted share. Gross margin was 42.0% and operating margin was -144404.5%. Operating activities generated -$9.9M of cash. At fiscal year end, Predictive Oncology held $52.9M in total assets against $5.2M in total liabilities, including $10.8M of cash and equivalents.
Open the full interactive Predictive Oncology financials → Quarterly statements, key ratios, valuation history and price charts.
Predictive Oncology Key Stats
| Share Price | $9.66 |
|---|---|
| Market Cap | $190.2M |
| Revenue YoY Growth | -92.3% |
| 52-Week Range | $1.41 – $13.60 |
| Shares Outstanding | 19.7 million (basic, 2026 Q2) |
Predictive Oncology Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.3M | $1.4M | $1.5M | $1.8M | $1.6M | $125,284 |
| Cost of Goods Sold | $447,192 | $487,024 | $505,107 | $634,796 | $826,137 | $28.6M |
| Gross Profit | $805,080 | $933,656 | $1.0M | $1.1M | $797,680 | $52,662 |
| Operating Income | -$25.4M | -$20.4M | -$26.0M | -$14.1M | -$10.9M | -$180.9M |
| Pre-Tax Income | -$25.9M | -$20.3M | -$25.7M | -$14.0M | -$12.7M | -$233.1M |
| Income Tax | $0 | -$661,658 | $0 | $0 | $0 | $0 |
| Net Income | -$25.9M | -$19.7M | -$25.7M | -$14.0M | -$12.7M | -$233.1M |
| Diluted EPS | -$649.81 | -$107.46 | -$105.77 | -$52.25 | -$34.83 | -$13.37 |
Predictive Oncology Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $3,618 | $8,674 | $35,311 | $3.2M |
| Net Income | -$77.7M | -$150.9M | -$7.7M | -$17.2M |
| Diluted EPS | -$107.25 | -$8.66 | -$0.36 | -$0.87 |
Predictive Oncology Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $678,332 | $28.2M | $22.1M | $8.7M | $734,673 | $10.8M |
| Current Assets | $1.5M | $29.5M | $23.4M | $10.1M | $2.2M | $42.8M |
| Total Assets | $13.1M | $43.8M | $25.7M | $14.4M | $5.0M | $52.9M |
| Current Liabilities | $9.3M | $3.2M | $3.9M | $4.0M | $3.6M | $4.3M |
| Total Liabilities | $10.4M | $3.5M | $4.0M | $6.1M | $5.2M | $5.2M |
| Shareholders' Equity | $2.6M | $40.3M | $21.8M | $8.3M | -$202,610 | $47.7M |
Predictive Oncology Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$12.3M | -$12.2M | -$12.4M | -$13.2M | -$11.0M | -$9.9M |
| Cash From Investing | -$167,456 | -$10.6M | -$475,697 | -$302,371 | — | — |
| Cash From Financing | $13.0M | $50.3M | $6.7M | $148,898 | — | — |
| Free Cash Flow | -$12.6M | -$13.1M | -$12.8M | -$13.5M | -$11.0M | -$9.9M |
Figures from Predictive Oncology's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Predictive Oncology financials page for every line item.
Predictive Oncology Company Profile
| Ticker | POAI |
|---|---|
| Exchange | Nasdaq |
| Industry | Finance Services |
| Headquarters | Pittsburgh, Pennsylvania |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001446159 |
Frequently Asked Questions
What was Predictive Oncology's revenue in fiscal 2025?
Predictive Oncology (POAI) reported revenue of $125,284 for fiscal 2025.
What is Predictive Oncology's annual revenue history?
Predictive Oncology's annual revenue by fiscal year: 2020: $1.3M; 2021: $1.4M; 2022: $1.5M; 2023: $1.8M; 2024: $1.6M; 2025: $125,284.
What was Predictive Oncology's net income in fiscal 2025?
Predictive Oncology reported net income of -$233.1M for fiscal 2025.
What was Predictive Oncology's earnings per share (EPS) in fiscal 2025?
Predictive Oncology's diluted EPS was -$13.37 for fiscal 2025 (adjusted for any later stock splits).
What was Predictive Oncology's revenue last quarter?
In its most recent reported quarter (2026 Q2), Predictive Oncology reported revenue of $3.2M.
How many shares of Predictive Oncology are outstanding?
Predictive Oncology reported a weighted average of 19.7 million basic shares outstanding in 2026 Q2.
What is Predictive Oncology's market cap?
Based on its latest closing price, Predictive Oncology (POAI) has a market capitalization of about $190.2M.
When does Predictive Oncology's fiscal year end?
Predictive Oncology's fiscal year end, as registered with the SEC, is December 31.
Where is Predictive Oncology headquartered?
Predictive Oncology lists its business address in Pittsburgh, Pennsylvania in its SEC filings.